BACKGROUND: Secreted phospholipases A(2) (sPLA(2)s) are released in plasma and other biologic fluids of patients with inflammatory, autoimmune, and allergic diseases. OBJECTIVE: We sought to evaluate sPLA(2) activity in the bronchoalveolar lavage fluid (BALF) of asthmatic patients and to examine the expression and release of sPLA(2)s from primary human lung mast cells (HLMCs). METHODS: sPLA(2) activity was measured in BALF and supernatants of either unstimulated or anti-IgE-activated HLMCs as hydrolysis of oleic acid from radiolabeled Escherichia coli membranes. Expression of sPLA(2)s was examined by using RT-PCR. The release of cysteinyl leukotriene (LT) C(4) was measured by means of enzyme immunoassay. RESULTS: Phospholipase A(2) (PLA(2)) activity was higher in the BALF of asthmatic patients than in the control group. BALF PLA(2) activity was blocked by the sPLA(2) inhibitors dithiothreitol and Me-Indoxam but not by the cytosolic PLA(2) inhibitor AZ-1. HLMCs spontaneously released a PLA(2) activity that was increased on stimulation with anti-IgE. This PLA(2) activity was blocked by dithiothreitol and Me-Indoxam but not by AZ-1. HLMCs constitutively express mRNA for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA(2)s. Anti-IgE did not modify the expression of sPLA(2)s. The cell-impermeable inhibitor Me-Indoxam significantly reduced (up to 40%) the production of LTC(4) from anti-IgE-stimulated HLMCs. CONCLUSIONS: sPLA(2) activity is increased in the airways of asthmatic patients. HLMCs express multiple sPLA(2)s and release 1 or more of them when activated by anti-IgE. The sPLA(2)s released by mast cells contribute to LTC(4) production by acting in an autocrine fashion. Mast cells can be a source of sPLA(2)s in the airways of asthmatic patients.
BACKGROUND: Secreted phospholipases A(2) (sPLA(2)s) are released in plasma and other biologic fluids of patients with inflammatory, autoimmune, and allergic diseases. OBJECTIVE: We sought to evaluate sPLA(2) activity in the bronchoalveolar lavage fluid (BALF) of asthmatic patients and to examine the expression and release of sPLA(2)s from primary human lung mast cells (HLMCs). METHODS: sPLA(2) activity was measured in BALF and supernatants of either unstimulated or anti-IgE-activated HLMCs as hydrolysis of oleic acid from radiolabeled Escherichia coli membranes. Expression of sPLA(2)s was examined by using RT-PCR. The release of cysteinyl leukotriene (LT) C(4) was measured by means of enzyme immunoassay. RESULTS:Phospholipase A(2) (PLA(2)) activity was higher in the BALF of asthmatic patients than in the control group. BALF PLA(2) activity was blocked by the sPLA(2) inhibitors dithiothreitol and Me-Indoxam but not by the cytosolic PLA(2) inhibitor AZ-1. HLMCs spontaneously released a PLA(2) activity that was increased on stimulation with anti-IgE. This PLA(2) activity was blocked by dithiothreitol and Me-Indoxam but not by AZ-1. HLMCs constitutively express mRNA for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA(2)s. Anti-IgE did not modify the expression of sPLA(2)s. The cell-impermeable inhibitor Me-Indoxam significantly reduced (up to 40%) the production of LTC(4) from anti-IgE-stimulated HLMCs. CONCLUSIONS: sPLA(2) activity is increased in the airways of asthmatic patients. HLMCs express multiple sPLA(2)s and release 1 or more of them when activated by anti-IgE. The sPLA(2)s released by mast cells contribute to LTC(4) production by acting in an autocrine fashion. Mast cells can be a source of sPLA(2)s in the airways of asthmatic patients.
Authors: Stephen Connolly; Colin Bennion; Sarah Botterell; Pamela J Croshaw; Catherine Hallam; Kim Hardy; Paul Hartopp; Clive G Jackson; Sarah J King; Louise Lawrence; Antonio Mete; David Murray; David H Robinson; Gillian M Smith; Linda Stein; Iain Walters; Edward Wells; W John Withnall Journal: J Med Chem Date: 2002-03-14 Impact factor: 7.446
Authors: Norbert Degousee; Farideh Ghomashchi; Eva Stefanski; Alan Singer; Brian P Smart; Niels Borregaard; Reinhardt Reithmeier; Thomas F Lindsay; Cornelia Lichtenberger; Walter Reinisch; Gerard Lambeau; Jonathan Arm; Jay Tischfield; Michael H Gelb; Barry B Rubin Journal: J Biol Chem Date: 2001-12-06 Impact factor: 5.157
Authors: Rao S Koduri; Juha O Grönroos; Veli J O Laine; Catherine Le Calvez; Gérard Lambeau; Timo J Nevalainen; Michael H Gelb Journal: J Biol Chem Date: 2001-11-02 Impact factor: 5.157
Authors: Ying Lai; Rob C Oslund; James G Bollinger; William R Henderson; Luis F Santana; William A Altemeier; Michael H Gelb; Teal S Hallstrand Journal: J Biol Chem Date: 2010-10-25 Impact factor: 5.157
Authors: Carole Guillaume; Christine Payré; Ikram Jemel; Louise Jeammet; Sofiane Bezzine; Gajendra S Naika; James Bollinger; Philippe Grellier; Michael H Gelb; Joseph Schrével; Gérard Lambeau; Christiane Deregnaucourt Journal: Infect Immun Date: 2015-03-30 Impact factor: 3.441
Authors: Andrea A Mosher; Kelly J Rainey; Brigitta Riley; Hayley S Levinson; Angela E Vinturache; Stephen L Wood; Donna M Slater Journal: Reprod Sci Date: 2014-01-18 Impact factor: 3.060
Authors: William R Henderson; Rob C Oslund; James G Bollinger; Xin Ye; Ying-Tzang Tien; Jun Xue; Michael H Gelb Journal: J Biol Chem Date: 2011-06-07 Impact factor: 5.157
Authors: Vincenzo Cerundolo; Graham Ogg; Rachael Jarrett; Mariolina Salio; Antonia Lloyd-Lavery; Sumithra Subramaniam; Elvire Bourgeois; Charles Archer; Ka Lun Cheung; Clare Hardman; David Chandler; Maryam Salimi; Danuta Gutowska-Owsiak; Jorge Bernardino de la Serna; Padraic G Fallon; Helen Jolin; Andrew Mckenzie; Andrzej Dziembowski; Ewa Izabela Podobas; Wojciech Bal; David Johnson; D Branch Moody Journal: Sci Transl Med Date: 2016-02-10 Impact factor: 17.956